



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 13 January 2021

Re: Freedom of Information Request
Ref: 291-2020

Thank you for your email dated the 14th December 2020, requesting information in relation to patient treatment figures and trials.

The information that you require is as follows:

Incidence and treatment of Myelofibrosis and Oesophageal cancer. Could you please answer the following questions for patients treated by your trust:

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Q1. Does your trust treat the following conditions? If not, which other trust do you refer these patients to?

- **Advanced oesophageal cancer – Yes, The Clatterbridge Cancer Centre (CCC) does treat this condition.**
- **Myelofibrosis - Yes, The Clatterbridge Cancer Centre (CCC) does treat this condition.**

Q2. Please provide the total number of patients treated in the last 6 months for:

- **Myelofibrosis - 6 (treated excludes watch and wait)**
- **Myelofibrosis – patients over the age 65 - 9 (treated excludes watch and wait)**
- **Oesophageal cancer (any type) - 132 patients**
- **Oesophageal adenocarcinoma – 71 patients**
- **Oesophageal squamous cell carcinoma - 53 patients**
- **Unresectable Oesophageal squamous cell carcinoma – Information not held - The Clatterbridge Cancer Centre (CCC) does not undertake surgery so will not know if a patient had surgery or not prior to attending CCC and that if surgery was not performed, whether this was due to the cancer being unresectable or due to another reason i.e. patient preference/co-morbidities**

Q3. For the oesophageal squamous cell carcinoma patients only, how many patients were treated in the past 6 months with:

- **Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) - 40 patients**
- **Any other systemic anti-cancer therapy – 11 patients**
- **Palliative care only - 21 patients had a palliative care appointment at CCC between July 2020-December 2020**

Q4. For myelofibrosis patients only, how many patients (of any age) were treated in the past 6 months with;

- **Ruxolitinib – 10 patients**
- **Hydroxyurea – Exempt under S.40**
- **Watch and wait approach – 19 patients**

Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Oesophageal – Open to Recruitment

Project Short Title	Project Full title	Project type	Principal Investigator	Recruited
SCOPE 2	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	Non-commercial portfolio	Eswar, Dr Chinnamani	15
CA209-76A (EAMS)	Clinical Characteristics, Outcomes And Quality Of Life In Patients With	Commercial portfolio	Boon, Dr Cheng	0

	Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy As Part Of An Early Access To Medicines Scheme (Eams) Program In The United Kingdom			
--	--	--	--	--

Oesophageal – Follow-up

Project Short Title	Project Full title	Project type	Principal Investigator	Recruited
CYTOFLOC	Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer – a feasibility study	Non-commercial portfolio	Sripadam, Dr Rajaram	6
NeoSCOPE	A randomised Phase II study of two preoperative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.	Non-commercial portfolio	Sripadam, Dr Rajaram	Exempt under S.40

Q6. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

Myelofibrosis – Open to Recruitment

Project Short Title	Project Full title	Project type	Principal Investigator	Recruited
BET Inhibitor 0610-02 (MANIFEST)	A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)	Commercial portfolio	Butt, Dr Nauman	0

Myelofibrosis – Follow-up

No studies to report.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>